Short answer
BioAge Labs, Inc. (BIOA) filed its Q2 2026 10-Q quarterly report on Aug 5, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $2M (up 1.6% year over year) with net income of −$26M.
Q2 2026 key financials · XBRL
- Revenue
- $2M
- +1.6% YoY · −11.6% QoQ
- Net income
- −$26M
- −21.0% YoY · −17.3% QoQ
- Operating margin
- -1196.8%
- EPS (diluted)
- −$0.59
- +1.7% YoY · −13.5% QoQ
Source: XBRL data from the BioAge Labs, Inc. (BIOA) Q2 2026 10-Q on SEC EDGAR. USD.
BioAge Labs, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No material changes from 2025 10-K identified in the provided Risk Factors section
- Clinical-trial failure risk, including unsuccessful preclinical studies, remains central to BGE-102 and APJ programs
- FDA approval risk, including delayed or denied product-candidate approvals, could materially impair commercialization
- Cash-burn risk, with $381.8 million accumulated deficit despite $381.3 million cash, equivalents, and marketable securities
- Customer concentration risk, with one customer representing 100% of revenue and accounts receivable
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other BioAge Labs, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.